Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PHA-543613 hydrochloride acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 695.00 |
Description | PHA-543613 hydrochloride acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia. |
Molecular Weight | 307.78 |
Formula | C15H18ClN3O2 |
CAS No. | 1586767-92-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PHA 543613 hydrochloride 1586767-92-1 PHA543613 Hydrochloride PHA-543613 Hydrochloride aPKC-I aPKC inhibitor PHA 543613 Hydrochloride aPKC I inhibitor inhibit